TROG Cancer Research
Members Login   CQMS Login  

TROG 16.03 (CORE)

Primary sponsor: The Institute of Cancer Research (UK)
Collaboratiing group: Trans Tasman Radiation Oncology Group (TROG)


A randomised trial of COnventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases 


CORE is a phase II/III, multicentre, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast and/or prostate cancer.    

Participating centres

Current participating centres (PDF)

Accrual Target


Current Accrual Graph

Current accrual graph (PDF)

Expected Date of Accrual Completion

October 2019

Trial chairperson

A/Prof David Pryor, Princess Alexandra Hospital, QLD
A/Prof Farshad Foroudi, Austin Health - Olivia Newton John Cancer and Wellness Centre, VIC 

Trial contact

Courtney Hill
TROG Trial Coordinating Centre
Phone: +61 2 4014 3900

Trial resources for TROG members

TROG 16.03 member page


We are thankful to our 14,500 patients who have participated in our research. Please continue the generous support.